New shot aims to cure hepatitis b without daily pills
NCT ID NCT07246889
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial tests an experimental drug called AHB-137 in 577 adults with HBeAg-negative chronic hepatitis B who are already on standard antiviral pills. Participants receive weekly injections of AHB-137 or a placebo for a set period, then stop all hepatitis B treatment. The main goal is to see if the virus stays undetectable 24 weeks after stopping all therapy, which would mean a functional cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AHB-137 injection (an experimental drug) given weekly under the skin, plus standard nucleoside analogue therapy
- What this could lead to
- If successful, this could offer a way to stop long-term antiviral pills and achieve a 'functional cure' where the virus is undetectable without ongoing medication.
- What could go wrong
- This is still an early-phase 3 trial, so results may not confirm benefit. There is a risk of side effects from the injection or that the virus returns after stopping treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AusperBio Investigational Site
Hefei, Anhui, China
-
AusperBio Investigational Site
Beijing, Beijing Municipality, China
-
AusperBio Investigational Site
Chongqing, Chongqing Municipality, China
-
AusperBio Investigational Site
Fuzhou, Fujian, China
-
AusperBio Investigational Site
Xiamen, Fujian, China
-
AusperBio Investigational Site
Lanzhou, Gansu, China
-
AusperBio Investigational Site
Foshan, Guangdong, China
-
AusperBio Investigational Site
Guangzhou, Guangdong, China
-
AusperBio Investigational Site
Shenzhen, Guangdong, China
-
AusperBio Investigational Site
Liuzhou, Guangxi, China
-
AusperBio Investigational Site
Nanning, Guangxi, China
-
AusperBio Investigational Site
Guiyang, Guizhou, China
-
AusperBio Investigational Site
Zunyi, Guizhou, China
-
AusperBio Investigational Site
Haikou, Hainan, China
-
AusperBio Investigational Site
Zhengzhou, Henan, China
-
AusperBio Investigational Site
Wuhan, Hubei, China
-
AusperBio Investigational Site
Changsha, Hunan, China
-
AusperBio Investigational Site
Nanjing, Jiangsu, China
-
AusperBio Investigational Site
Zhenjiang, Jiangsu, China
-
AusperBio Investigational Site
Nanchang, Jiangxi, China
-
AusperBio Investigational Site
Changchun, Jilin, China
-
AusperBio Investigational Site
Shenyang, Liaoning, China
-
AusperBio Investigational Site
Shanghai, Shanghai Municipality, China
-
AusperBio Investigational Site
Taiyuan, Shanxi, China
-
AusperBio Investigational Site
Xi’an, Shanxi, China
-
AusperBio Investigational Site
Chengdu, Sichuan, China
-
AusperBio Investigational Site
Kunming, Yunnan, China
-
AusperBio Investigational Site
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data